BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Zhang X, Luo H, Wu C, Yu M, Liu D, Xi H, Zhou Y, An Y, Xu X. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. Oncotarget 2017;8:90916-24. [PMID: 29207613 DOI: 10.18632/oncotarget.18701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Pariente A, Arpurt JP, Rémy AJ, Rosa-Hézode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le eaBricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagège H, Lesgourgues B; Association nationale des gastroentérologues des hôpitaux (ANGH). Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH). Presse Med 2019;48:e101-10. [PMID: 30853287 DOI: 10.1016/j.lpm.2018.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Chopra D, Bhandari B. Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment? Infect Disord Drug Targets 2020;20:2-15. [PMID: 30113002 DOI: 10.2174/1871526518666180816101124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]